



As a translational research institute, the Ontario Institute for Cancer Research (OICR) provides a number of clinical- and industry-relevant services to support translation of your research work. You may access these supports directly or consult with one of our Molecular Oncology Core Research Resources (MOCRR) team members to collaborate and learn more.

## Clinical evaluation supports

Clinical trials and other evaluative studies are essential for assessing new methods to treat, diagnose, and prevent cancer. OICR has a series of programs and funding opportunities which support clinical evaluation efforts.

- Funding from OICR's [Clinical Translation Pathway](#) supports the clinical translation of innovative cancer research. Both preclinical projects and early phase (I, II) clinical trials are eligible for funding.
- The [Ontario Clinical Research Ethics Board \(OCREB\)](#) is an innovative, oncology-specialized Research Ethics Board (REB) serving hospitals in Ontario that conduct cancer clinical trials. OCREB operates a centralized REB model which streamlines the review process, minimizes redundancy, promotes consistency, and saves the time and cost of having the study reviewed by an REB at every participating institution (study site).
- The [Window of Opportunity \(WOO\) Network](#) conducts clinical trials in the “window” period of newly-diagnosed patients prior to their cancer surgery, to understand the biological effects of novel cancer therapies. Funding is available for WOO studies.
- The [Canadian Cancer Clinical Trials Network \(3CTN\)](#), provides direct support (including funding and operational support) to cancer centres, investigators and trial teams to conduct academic cancer trials, through core and incentive funding participation in, and recruitment to, academic cancer trials.

## Healthcare implementation supports

To improve the number of research discoveries that are adopted into clinical practice, and improve uptake by the healthcare system, OICR launched the [Implementation Lab \(IL\)](#). The IL primarily supports the evaluation of validated and approved biomarkers, and engages with policymakers to address the needs of diagnostic testing. As newer biomarkers become clinically validated, IL can provide guidance and support on the translation of the biomarker and assay into clinical practice in collaboration with provincial partners. Funding for projects to study ways to speed up the appropriate adoption of innovations is available.

## Commercialization supports

OICR works with its partner [Fight Against Cancer Innovation Trust \(FACIT\)](#) to maximize the value of intellectual property and capture the economic benefits through commercialization. In particular, FACIT provides commercial planning for early-stage research and funding to support commercialization opportunities. Funding levels include pitch competitions for new cancer innovations (\$100,000), early stage proof-of-concept studies (\$50,000-\$200,000), and early stage development projects (\$1M-\$5M).